clinical trial · NCT04826185
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
Imbria Pharmaceuticals, Inc.·phase2·completed·n = 67
Non-obstructive Hypertrophic CardiomyopathyIMB-1018972Placebo
brief summary
The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.
started
Jun 14, 2021
primary completion
Sep 18, 2023
completion
Sep 18, 2023
last updated
Apr 23, 2024
official title
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol